INDUCED APOPTOSIS IN AGE RELATED MACULAR DEGENERATION
年龄相关性黄斑变性中诱导细胞凋亡
基本信息
- 批准号:6384848
- 负责人:
- 金额:$ 33.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-08-01 至 2003-07-31
- 项目状态:已结题
- 来源:
- 关键词:aging angiogenesis angiogenesis inhibitors apoptosis cell growth regulation confocal scanning microscopy disease /disorder model human tissue immunocytochemistry laboratory mouse macular degeneration polymerase chain reaction retina circulation disorder retinal pigment epithelium tissue /cell culture vascular endothelium
项目摘要
DESCRIPTION: (Applicant's Description)
Neovascularization is the major cause of vision loss in patients with age-
related macular degeneration (AMD), diabetic retinopathy, and retinopathy of
prematurity. AMD is the leading cause of blindness in the Western world in
individuals over 60 years of age. Since a large proportion of the population
is living well beyond this age, this is a significant threat to the quality of
life in elderly people. In patients with AMD new vessel growth (angiogenesis)
beneath the retina from the underlying choroid (choroidal neovascularization
or CNV) is the major or cause of severe visual loss in these patients. We
recently examined the role of apoptosis in controlling new vessel growth in
the eye by examining the function of two molecules, Fas (CD95) and FasL
(CD95L). Our studies revealed that FasL plays a significant role in
controlling CNV, where FasL+ retinal pigment epithelial cells (RPE) prohibit
the growth and development of new Fas+ subretinal vessels that damage vision.
Studies described in this proposal are designed to thoroughly understand the
role of Fas/FasL and apoptosis in the pathogenesis of AMD. We propose 5 aims.
Aim 1 we will more completely evaluate the role of Fas/FasL in CNV in a mouse
model using normal, Fas, and FasL defective mice. In Aim 2 we will study cell
endothelial cells derived from the choroid and compare these to endothelial
cells derived from other areas. We will examnine cell death, proliferation,
and differentiation using in vitro models and characterize the role of the Fas
antigen in these processes. Aim 3 will contains experiments to explore the
function of FasL on RPE cells and determine how growth factors and MMP
inhibitors can affect FasL function in these cells that are crucial in
controlling CNV. Aim 4 will explore potential treatment modalities in CNV
applying the knowledge we have gained concerning the regulation of FasL
expression to the animal model. Finally, studies in Aim 5 will evaluate
clinical specimens from patients AMD for Fas/FasL expression. Our studies
should provide important insights into one of the leading causes of blindness
in the western world.
描述:(申请人描述)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Almon Ferguson其他文献
Thomas Almon Ferguson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Almon Ferguson', 18)}}的其他基金
Modulation of cone photoreceptor function by autophagy
自噬调节视锥光感受器功能
- 批准号:
10681018 - 财政年份:2023
- 资助金额:
$ 33.58万 - 项目类别:
Immune Privilege, Müller cells, and Autophagy
免疫特权、Müller 细胞和自噬
- 批准号:
10680566 - 财政年份:2022
- 资助金额:
$ 33.58万 - 项目类别:
Immune Privilege, Müller cells, and Autophagy
免疫特权、Müller 细胞和自噬
- 批准号:
10501886 - 财政年份:2022
- 资助金额:
$ 33.58万 - 项目类别:
相似国自然基金
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
- 批准号:81200692
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
- 批准号:
21H03019 - 财政年份:2021
- 资助金额:
$ 33.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
- 批准号:
20K08542 - 财政年份:2020
- 资助金额:
$ 33.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
- 批准号:
9813883 - 财政年份:2019
- 资助金额:
$ 33.58万 - 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
- 批准号:
17K08457 - 财政年份:2017
- 资助金额:
$ 33.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
- 批准号:
26461102 - 财政年份:2014
- 资助金额:
$ 33.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
- 批准号:
23591763 - 财政年份:2011
- 资助金额:
$ 33.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 33.58万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7351352 - 财政年份:2008
- 资助金额:
$ 33.58万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
8002099 - 财政年份:2008
- 资助金额:
$ 33.58万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7537218 - 财政年份:2008
- 资助金额:
$ 33.58万 - 项目类别:














{{item.name}}会员




